In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in ...

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...